• Regentis Biomaterials

  Participated · Series D · Feb 2016

  Regentis Biomaterials develops cartilage repair solutions, with offices in Princeton, New Jersey and Or Akiva, Israel. Its core product, GelrinC, is a proprietary hydrogel invented at the Technion that is implanted as a liquid and cured in‑situ to form a resorbable implant gradually replaced by regenerated cartilage. Earlier trials in Europe and Israel showed GelrinC provided patients relief from knee pain and improved function to return to normal activities. The company closed a $15M Series D led by Haisco Pharmaceutical Group and intends to use the proceeds to conduct a pivotal clinical trial of GelrinC in the United States aimed at obtaining FDA marketing approval. As part of the investment, Haisco will serve as GelrinC's exclusive distributor in China. Regentis is led by CEO Alastair Clemow, Ph.D., and counts Medica Partners, SCP Vitalife Partners, Generali Financial Holdings and Technion funds among its investors. Regentis Biomaterials develops GelrinC, a biodegradable implant intended to enhance growth of articular cartilage in damaged knee joints. The company is based in Or Akiva, Israel and Princeton, NJ and is led by CEO and President Dr. Alastair Clemow. GelrinC is currently an investigational device; prior pre-clinical studies demonstrated its ability to regrow cartilage. Regentis is conducting a multi-center pilot study in Europe and Israel to evaluate the safety and performance of GelrinC. The company intends to use the new funding to expand clinical efforts for the implant. GelrinC is not available for sale in the U.S., Europe or Israel while clinical evaluation is ongoing.

• Ivenix

  Participated · Equity · Sep 2015

  Ivenix develops a next-generation infusion system that integrates advanced information technology with a redesigned pump platform to improve accuracy, efficiency, and safety. The Ivenix Infusion System provides immediate, secure access to patient-specific infusion and pump management information and features an intuitive, smartphone-like user interface. The product combines fundamentally new pump technology with IT capabilities to address large-volume infusion delivery and interoperability with hospital EMRs. Ivenix plans to pursue FDA clearance and will use the financing to expand its team ahead of commercial launch. The company highlights a $6 billion global infusion pump market and frames its system as a response to persistent patient safety issues and lack of innovation. Ivenix is headquartered in Amesbury, Massachusetts; the U.S. FDA has not yet reviewed the Ivenix Infusion System. Ivenix provides an infusion management system for hospitals that combines a new pump delivery system, a smartphone-like user interface and an information technology system that shares infusion data with the patient’s electronic medical record. The product is designed to improve patient safety and workflow efficiency in clinical settings. The company is led by Jesse Ambrosina and is based in Amesbury, MA. Ivenix closed a $42M equity financing to support its operations. The new funding will support the company’s efforts to enter the global infusion market.

• MST Medical Surgery Technologies

  Participated · Series C · Jul 2015

  MST develops image‑guided surgical systems built on a proprietary image analytic technology platform; its flagship product is AutoLap®, an FDA‑cleared and CE‑approved image‑guided laparoscope positioning system. AutoLap® offers surgeons hands‑free, natural control of laparoscopic procedures with minimal user interaction and is aimed at the large minimally invasive surgery market. The company says healthcare providers benefit from cost‑effective technology that can enable more efficient procedures. MST is privately held, was founded in 2005, and is based in Yokneam, Israel. Management plans to use the recent investment primarily to expand marketing and sales of AutoLap® in the U.S., Europe and China. As part of the deal, the lead investor Haisco will serve as AutoLap®’s exclusive distributor in China.

• Sensible Medical Innovations

  Participated · Equity · Nov 2013

  Sensible Medical develops a non-invasive thoracic fluid status monitor as its flagship product. The company raised $20 million in its latest financing to advance clinical evidence and commercialization. Boston Scientific led the round and is collaborating with Sensible on launch activities. The partners are working to obtain certification for the monitor in the U.S., Europe, and Japan. Other investors in the round included Shanghai LongTec Medical Technology Co., SCP Vitalife Partners, and Genesis Partners. Sensible plans to use the funds to gather additional clinical data and commercialize the product globally. Sensible Medical is developing a non-invasive imaging device that marries medical and information technology to examine internal organs and monitor congestive heart failure. The company says the device could replace exploratory surgery currently needed to detect congestive heart failure. The technology has been tested in animals and Sensible is preparing to test it in humans as it moves toward U.S. Food and Drug Administration approval. Founded in 2007 by CEO Amir Ronen, the Israeli company is opening its first U.S. office in Columbus, Ohio to work primarily with Dr. William Abraham of Ohio State University and to test the device with Ohio State and the Cleveland Clinic. In June Sensible Medical won a $7 million investment from SPC Vitalife and Genesis Partners, and in May it was among recipients of a shared $1 million award from the Global Cardiovascular Innovation Center. The Columbus office currently has one employee and the company expects to add more staff as U.S. testing progresses.

• Avedro

  Participated · Series D · Mar 2013

  Avedro is a Waltham, MA–based ophthalmic pharmaceutical and medical device company led by CEO Reza Zadno, PhD. The company has developed a patented corneal cross-linking technology that includes drug formulations and medical devices, which is approved for sale in numerous countries. Avedro is developing proprietary corneal remodeling products to treat keratoconus, corneal ectasia and to provide refractive correction as an alternative to contacts and eyeglasses. It secured $25M in financing to support its programs. The company plans to use the funds for product development, clinical studies and commercial efforts, including expansion of sales and reimbursement support. Avedro’s board gained Hongbo Lu, PhD, as a representative of the lead investor in connection with the financing. Avedro develops and commercializes corneal cross-linking pharmaceutical and device therapies, including FDA‑approved Photrexa Viscous, Photrexa and the KXL System. The company sells additional capital equipment and formulations outside the U.S., such as UV‑X devices, the KXL and Mosaic Systems, and VibeX and MedioCROSS. Avedro announced a combined $42 million equity and debt financing to support commercial expansion and pipeline and clinical development programs. It has opened a new manufacturing facility in Burlington, Massachusetts, near its Waltham headquarters, to increase production capacity and support a global supply chain. The facility employs 5S, Lean and Six Sigma methodologies and will accommodate an anticipated year‑over‑year increase in large capital equipment production in 2017. Avedro is also expanding its corporate team to support growth and broader commercialization efforts. Avedro develops corneal cross-linking platforms and related pharmaceuticals, including the KXL and Mosaic systems and formulations such as VibeX and MedioCROSS. Its Mosaic System performs the PiXL procedure, intended to deliver non-surgical correction of myopia and improve cataract surgery outcomes. The company distributes products outside the United States through a network of ophthalmic medical device distributors; its products are not approved for sale in the United States. Avedro has re-submitted an NDA to the U.S. FDA for its corneal cross-linking technology and anticipates a PDUFA action date in April 2016. Proceeds from recent financing are intended to strengthen the balance sheet, expand global distribution of KXL, commence commercialization of Mosaic outside the U.S., and support potential U.S. commercialization if FDA approval is received. The company describes its work as advancing the science and technology of corneal cross-linking and refractive correction. Avedro develops corneal crosslinking capital equipment and related pharmaceutical (riboflavin) products used to treat multiple corneal pathologies and to improve LASIK outcomes via its Lasik Xtra procedure. The company’s products have received CE Mark and have been commercially launched in 32 countries outside the United States; Avedro’s products are not for sale in the U.S. It reports that nearly 50,000 Lasik Xtra procedures were performed worldwide in 2012. Avedro is preparing to launch a new device platform that it says will open significant new procedure opportunities previously demonstrated in early trials. Its technology is being evaluated in three Phase III clinical studies in the U.S. involving more than 100 sites. The company plans to pursue U.S. FDA approval and expand applications of corneal crosslinking into cataract and refractive surgery. Avedro is a privately held ophthalmic device and pharmaceutical company based in Waltham, MA developing systems and procedures to biomechanically strengthen and modify the cornea. The company produces and sells the KXL System for performing Lasik Xtra and Accelerated Cross-linking and the Vedera System for performing Keraflex, an incisionless thermal procedure to flatten the cornea. Both devices are CE Marked and commercially available outside the United States. Avedro positions KXL as a way to enhance the LASIK market by offering patients added security and Vedera as able to induce refractive change without removing tissue. The company completed a $25 million Series C and plans to use the proceeds to expand commercial operations of the Vedera and KXL Systems outside the United States and to seek U.S. FDA clearance.

No current team members are available.